Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/24/2868241/0/en/Centessa-Pharmaceuticals-Announces-Pricing-of-100-Million-Public-Offering-of-American-Depositary-Shares.html
https://www.globenewswire.com/news-release/2024/04/23/2868154/0/en/Centessa-Pharmaceuticals-Announces-100-Million-Proposed-Public-Offering-of-American-Depositary-Shares.html
https://www.globenewswire.com/news-release/2024/04/22/2866726/0/en/Centessa-Pharmaceuticals-Announces-Open-IND-for-ORX750-Proof-of-Concept-Data-in-Sleep-Deprived-Healthy-Volunteers-Planned-for-2H-2024.html
https://www.fiercebiotech.com/biotech/biotech-naming-trends-bypass-buzzwords-and-business-speak-build-whimsical-memorable-brands
https://www.globenewswire.com/news-release/2024/03/28/2854497/0/en/Centessa-Pharmaceuticals-Reports-Business-Highlights-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2023.html
https://www.globenewswire.com//news-release/2024/02/22/2833652/0/en/Centessa-Pharmaceuticals-to-Participate-in-TD-Cowen-s-44th-Annual-Health-Care-Conference.html
https://www.globenewswire.com//news-release/2024/02/09/2826709/0/en/Centessa-Pharmaceuticals-to-Present-Additional-52-Weeks-of-Continuous-Treatment-Data-from-Third-Year-Part-5-of-Ongoing-Phase-2a-Study-of-SerpinPC-for-the-Treatment-of-Hemophilia-at.html
https://www.globenewswire.com//news-release/2023/12/13/2795497/0/en/Centessa-Pharmaceuticals-to-Present-at-the-42%E2%81%BF%E1%B5%88-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/10/2793464/0/en/Centessa-Pharmaceuticals-Announces-New-Data-from-an-Additional-52-Weeks-of-Continuous-Treatment-from-Third-Year-Part-5-of-Ongoing-Phase-2a-Study-of-SerpinPC-for-the-Treatment-of-He.html
https://www.globenewswire.com//news-release/2023/11/27/2786530/0/en/Anaptys-Expands-Immune-Cell-Modulator-Pipeline-with-Exclusive-License-to-BDCA2-Modulator-Antibody-Portfolio-from-Centessa-Pharmaceuticals.html